Novavax, Inc. (NVAX): Price and Financial Metrics

Novavax, Inc. (NVAX)

Today's Latest Price: $126.98 USD

4.58 (3.74%)

Updated Jan 22 4:00pm

Add NVAX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

NVAX Stock Summary

  • Price to trailing twelve month operating cash flow for NVAX is currently 125.1, higher than 95.69% of US stocks with positive operating cash flow.
  • NVAX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 98.84% of US stocks.
  • As for revenue growth, note that NVAX's revenue has grown 1,181.88% over the past 12 months; that beats the revenue growth of 99.34% of US companies in our set.
  • Stocks that are quantitatively similar to NVAX, based on their financial statements, market capitalization, and price volatility, are DRNA, CTMX, NKTR, XNCR, and AGIO.
  • NVAX's SEC filings can be seen here. And to visit Novavax Inc's official web site, go to

NVAX Stock Price Chart Interactive Chart >

Price chart for NVAX

NVAX Price/Volume Stats

Current price $126.98 52-week high $189.40
Prev. close $122.40 52-week low $6.26
Day low $121.43 Volume 2,598,500
Day high $127.21 Avg. volume 3,223,671
50-day MA $115.69 Dividend yield N/A
200-day MA $93.32 Market Cap 8.08B

Novavax, Inc. (NVAX) Company Bio

Novavax, Inc. focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company was founded in 1987 and is based in Gaithersburg, Maryland.

NVAX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$126.98$27645.64 22008%

Below please find a table outlining a discounted cash flow forecast for NVAX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Novavax Inc ranked in the 98th percentile in terms of potential gain offered. Our DCF model suggests the stock is undervalued by 22116%; returns of such proportions should be viewed with some skepticism, though. The most interesting components of our discounted cash flow analysis for Novavax Inc ended up being:

  • The business' balance sheet suggests that 5% of the company's capital is sourced from debt; this is greater than only 17.74% of the free cash flow producing stocks we're observing.
  • Novavax Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -17.58. This coverage rate is greater than that of only 5.84% of stocks we're observing for the purpose of forecasting via discounted cash flows.
  • As a business, Novavax Inc experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than just 0% of stocks generating free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Novavax Inc? See THC, BMRN, KMDA, VRTX, and AMEH.

NVAX Latest News Stream

Event/Time News Detail
Loading, please wait...

NVAX Latest Social Stream

Loading social stream, please wait...

View Full NVAX Social Stream

Latest NVAX News From Around the Web

Below are the latest news stories about Novavax Inc that investors may wish to consider to help them evaluate NVAX as an investment opportunity.

Elderly begin to drop out of Novavax vaccine trial to get Pfizer and Moderna shots - Washington Post

Novavax’s ([[NVAX]] -2.2%) Phase 3 trial of its COVID-19 vaccine candidate, NVX-CoV2373 has received drop-out requests from some participants who are 65 or older, after New York announced vaccination program for the above age group with one of two authorized vaccines, by Pfizer and Moderna, reported Washington Post.One Long Island physician told...

Seeking Alpha | January 20, 2021

Top Small Cap Stocks for February 2021

These are the small cap stocks with the best value, fastest growth, and most momentum for February 2021.

Yahoo | January 20, 2021

S.Korea may secure additional COVID-19 vaccines from Novavax, Moon says

South Korea may secure additional coronavirus vaccines for 20 million people from U.S. drugmaker Novavax Inc, President Moon Jae-in said, according to a statement from the presidential office on Wednesday. Novavax entered into a development and supply agreement for its vaccine with South Korea's SK bioscience Co last year, according to a statement in August. Moon visited SK bioscience's work site on Wednesday and said that the agreement between Novavax and SK bioscience "raised the possibility of securing vaccines for an additional 20 million people," the statement said.

Yahoo | January 20, 2021

AstraZeneca's (AZN) Enhertu Gets FDA Nod for Gastric Cancer

AstraZeneca's (AZN) Enhertu is the first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer.

Yahoo | January 19, 2021

Corona Virus Vaccines Market 2020-2030 | Pfizer Inc., AstraZeneca plc, Novavax, Inc.

Global Corona Virus Vaccines Market: Overview COVID-19 refers to a viral infection occurred due to a corona virus named SARS-CoV-2. This virus attacks the respiratory tract of an individual. The COVID-19 virus is communicable disease and can spread due to direct

OpenPR | January 18, 2021

Read More 'NVAX' Stories Here

NVAX Price Returns

1-mo -0.52%
3-mo 36.35%
6-mo -5.19%
1-year 1,557.70%
3-year 184.71%
5-year -4.09%
YTD 13.87%
2020 2,701.76%
2019 -89.18%
2018 48.39%
2017 -1.59%
2016 -84.98%

Continue Researching NVAX

Want to see what other sources are saying about Novavax Inc's financials and stock price? Try the links below:

Novavax Inc (NVAX) Stock Price | Nasdaq
Novavax Inc (NVAX) Stock Quote, History and News - Yahoo Finance
Novavax Inc (NVAX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8005 seconds.